Cas No.: | 3717-88-2 |
Chemical Name: | Flavoxate |
Synonyms: | flavoxate hydrochloride;1-piperidineethanol,3-methyl-4-oxo-2-phenyl-4h-1-benzopyran-8-carboxylate,h;2-piperidinoethyl-3-methyl-4-oxo-2-phenyl-4h-1-benzopyran-8-carboxylatehydro;3-methyl-4-oxo-2-phenyl-4h-1-benzopyran-8-carboxylicaci2-piperidinoethyl;bladderon;flaroxatehydrochloride;genurin;nsc-114649;piperidinoethyl-3-methylflavone-8-carboxylatehydrochloride;spasuret;REC-7-0040;FLAVOXATE HCL;DW-61;3-METHYL-4-OXO-2-PHENYL-4H-1-BENZOPYRAN-8-CARBOXYLIC ACID 2-(1-PIPERIDINYL)ETHYL ESTER HYDROCHLORIDE;3-METHYL-4-OXO-2-PHENYL-4H-BENZOPYRAN-8-CARBOXYLIC ACID 2-PIPERIDINYL ETHYL ESTER HYDROCHLORIDE;2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate,hydrochloride;DW61;flavoxate;Flavoxatum;Flavoxato;2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate;Flavossato [DCIT];Flavoxate [INN:BAN];Flavoxatum [INN-Latin];Flavoxato [INN-Spanish];4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester;2-piperidinoethyl 3-methylflavone-8-carboxylate;Spasuret hydrochloride;3E74Y80MEY;2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate;2-Piperidinoeth |
SMILES: | O(C(C1=C([H])C([H])=C([H])C2C(C(C([H])([H])[H])=C(C3C([H])=C([H])C([H])=C([H])C=3[H])OC1=2)=O)=O)C([H])([H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] |
Formula: | C24H25NO4 |
M.Wt: | 391.4596 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Flavoxate Hydrochloride(DW-61 Hydrochloride) is a muscarinic AChR antagonist used in various urinary syndromes and as an antispasmodic.Target: mAChRFlavoxate displaces [3H]nitrendipine on the Ca2+ channels binding sites with IC50 of 254 μM [1]. Flavoxate (>10 μM) suppresses carbachol-induced contractions in isolated rat detrusor strips with pD value of 4.55. Flavoxate (>10 μM) suppresses Ca2+-induced contractions in isolated rat detrusor strips with pIC50 value of 4.92 [2]. Flavoxate (0.01 μM ?10 μM) inhibits CAMP formation in a concentration-dependent manner in membranes from the rat striatum and cerebral cortex, an action which is completely abolished by pretreating the membranes with pertussis toxin (PTX) [3].Flavoxate (10mg/kg) suppresses both the an initial, rapidly rising phasic contraction (phase 1) and the tonic contraction (phase 2) contractions to the same extent in rats. Flavoxate (10mg/kg) abolishes the bladder contractions without causing any change in the amplitude of the contractions in rats. Flavoxate (3 mg/kg) abolishes the efferent neural activity and the associated bladder contractions for about 10 minutes without changing the baseline vesical pressure in rats. ICV-injected (50 to 200 μg/rat) or IT-injected (100 to 200 μg/rat) Flavoxate abolishes rhythmic bladder contractions during and after injection for five to 15 minutes in a dose-dependent manner in rats [2]. Flavoxate (3 mg/kg, i.v.) abolishes rhythmic bladder contractions and the maximal intervals of voiding contractions is 7.20 min [3]. |
References: | [1]. Dansette, P.M., M. Jaoen, and C. Pons, HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins. Exp Toxicol Pathol, 2000. 52(2): p. 145-8. [2]. Kimura, Y., et al., Mechanisms of the suppression of the bladder activity by flavoxate. Int J Urol, 1996. 3(3): p. 218-27. [3]. Oka, M., et al., Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res, 1996. 727(1-2): p. 91-8. |